Read more

September 25, 2011
2 min read
Save

Recurrence, survival rates similar for breast conservation, mastectomy in younger women

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

ASCO 2011 Breast Cancer Symposium

SAN FRANCISCO — Recurrence and survival rates are similar after breast-conservation surgery and mastectomy in women aged younger than 40 years with breast cancer, according to two studies.

In a retrospective study of the medical records of 628 women aged 40 years and younger, Julliette Buckley, MD, a fellow in breast surgery at Massachusetts General Hospital, and colleagues analyzed the rates of local recurrence, distant recurrence and OS among those diagnosed with up to stage III breast cancer between 1996 and 2008.

The rate of locoregional recurrence was 5.56% at 5 years and 12.11% at 10 years. There was no difference in the rate of locoregional occurrence between the group of patients who underwent breast-conserving therapy and the group of patients who underwent mastectomy: 7.34% vs. 7.4%.

“Prior studies have shown that younger women have a higher rate of local recurrence after lumpectomy, but our study suggests that lumpectomy is a safe option for young women,” Buckley said. “We believe that awareness of the genetic risk of breast cancer, advances in screening for breast cancer, and improvements in systemic and radiation therapy have contributed to longer OS for young women with breast cancer.”

In another study, Usama Mahmood, MD, a fellow in radiation oncology at The University of Texas MD Anderson Cancer Center, and colleagues found that breast-conservation therapy results in similar survival outcomes compared with mastectomy in younger women with early-stage breast cancer.

The researchers used the SEER database to analyze OS and cancer-specific survival among 14,760 women aged 20 to 39 years who were diagnosed with early-stage breast cancer. After controlling for variables, including diagnosis, age, race/ethnicity, tumor grade, PR status, tumor size and lymph node status, they found there was no difference in OS between the two groups.

Among those who underwent breast-conservation therapy, OS at 5, 10 and 15 years was 92.5%, 83.5% and 77%, respectively. Among those who underwent mastectomy, OS at 5, 10 and 15 years was 91.9%, 83.6% and 79.1%, respectively.

“Our findings provide reassurance that breast-conservation therapy leads to similar survival outcomes as mastectomy, even among younger women with early-stage breast cancer,” Mahmood said. “Women should be counseled appropriately regarding their treatment options and should not choose a mastectomy based on an assumption of improved survival.”

For more information:

  • Buckley J. #70. Presented at: 2011 Breast Cancer Symposium; Sept. 8-10; San Francisco.

PERSPECTIVE

It’s very important that we periodically revisit conventional wisdom, and in this case, it is an important revisitation to the conventional wisdom that young women with breast cancer need to have a mastectomy. There are certainly differences in the biology of the disease in young women compared to older women. But this contemporary theory reflects management that has likely been influenced by newer modalities such as the use of breast MRI for screening, and therefore better selection of patients who might better undergo breast-conservation therapy compared to mastectomy. Also, a greater number of women are being tested for BRCA to identify those at risk. It’s reassuring to younger women that young age alone does not seem to mandate the need for mastectomy. One needs to look at other variables, independent of age.

Andrew D. Seidman, MD
Attending Physician, Memorial Sloan-Kettering Cancer Center

Earn CME this spring at the HemOnc Today Breast Cancer Review & Perspective meeting to be held March 23-24, 2012 at the Hilton San Diego Bayfront. See details at HemOncTodayBreastCancer.com.

Twitter Follow HemOncToday.com on Twitter.